IN2014MN01640A - - Google Patents

Info

Publication number
IN2014MN01640A
IN2014MN01640A IN1640MUN2014A IN2014MN01640A IN 2014MN01640 A IN2014MN01640 A IN 2014MN01640A IN 1640MUN2014 A IN1640MUN2014 A IN 1640MUN2014A IN 2014MN01640 A IN2014MN01640 A IN 2014MN01640A
Authority
IN
India
Prior art keywords
novel
preparation
relates
lactam compounds
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Burkhard Klenke
Irith Wiegand
Guido Schiffer
Oesterhelt Heike Broetz
Samarendra N Maiti
Jehangir Khan
Andhe Reddy
Zhixiang Yang
Mostafa Hena
Guofeng Jia
Ou Ligong
Hong Liang
Judy Yip
Chuanjun Gao
Sabiha Tajammul
Rahim Mohammad
Ganguli Biswajeet
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of IN2014MN01640A publication Critical patent/IN2014MN01640A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN1640MUN2014 2012-01-24 2013-01-23 IN2014MN01640A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12152279 2012-01-24
PCT/EP2013/051217 WO2013110643A1 (en) 2012-01-24 2013-01-23 Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents

Publications (1)

Publication Number Publication Date
IN2014MN01640A true IN2014MN01640A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-05-22

Family

ID=47603723

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1640MUN2014 IN2014MN01640A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-01-24 2013-01-23

Country Status (42)

Country Link
US (2) US9556165B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2806873B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP5869701B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR102036393B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104203237A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP2014007880A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR089796A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013211575B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014017968A8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2862338C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2014001956A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO7101240A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CU (1) CU24273B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1117955T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2806873T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA027126B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP14010249A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2592403T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20161171T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE030452T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL233805A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014MN01640A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2806873T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA35905B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME02532B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX346602B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY173843A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ626951A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20142345A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12014501671B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2806873T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2806873T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS55210B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201403930XA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2806873T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SM (1) SMT201600354B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN (1) TN2014000297A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI659953B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA110880C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY34585A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013110643A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201405057B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015103583A1 (en) * 2014-01-06 2015-07-09 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
ES2719136T3 (es) 2014-03-24 2019-07-08 Novartis Ag Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
CN105175335B (zh) * 2015-08-13 2017-11-03 南阳师范学院 一种3‑(3,3‑二氯烯丙氧基)‑1‑甲基吡唑‑5‑甲酰胺衍生物及其制备方法
SMT202000480T1 (it) 2015-09-23 2020-11-10 Novartis Ag Sali e forme solide di un antibiotico monobactamico
CN108368040B (zh) 2015-12-15 2024-08-23 默沙东有限责任公司 二芳基单环β-内酰胺化合物及其用于治疗细菌感染的方法
US10407421B2 (en) 2016-03-07 2019-09-10 Merck Sharp & Dohme Corp Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
CN107641119B (zh) 2016-07-21 2019-11-08 中国科学院上海药物研究所 单环β-内酰胺-铁载体轭合物及其制备方法和用途
IL264686B2 (en) 2016-08-26 2024-07-01 Codexis Inc Engineered imine reductases and methods for reversible amination of ketone and amine compounds
JP2019535724A (ja) 2016-11-18 2019-12-12 アイキュリス アンチ−インフェクティブ キュアズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 細菌感染症の治療に使用するためのアミジン置換β−ラクタム化合物のリポソーム製剤
US20190365720A1 (en) 2016-11-18 2019-12-05 Aicuris Anti-Infective Cures Gmbh Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
CN110312715A (zh) 2016-12-21 2019-10-08 艾库里斯有限及两合公司 用于抗生素耐药性细菌菌株感染的使用脒取代的β-内酰胺化合物和β-内酰胺酶抑制剂的组合疗法
AU2018304841A1 (en) 2017-07-18 2020-02-06 Bayer Aktiengesellschaft Substituted 3-heteroaryloxy-1H-pyrazoles and salts thereof and their use as herbicidal active substances
TW201920163A (zh) 2017-07-28 2019-06-01 德商艾庫里斯抗感染治療有限公司 (2s)‐2‐[[(z)‐[1‐(2‐胺基‐4‐噻唑基)‐2‐[[(3s)‐2,2‐二甲基‐4‐側氧基‐1‐(磺氧)‐3‐吖丁啶基]胺基]‐2‐氧亞乙基]胺基]氧基]‐3‐[4‐[亞胺基[(3r)‐3-哌啶基胺基]甲基]苯氧基]-丙酸之晶型
EP3661933B1 (en) 2017-08-02 2022-03-23 Novartis AG Process for preparing 1-(((z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid
PE20201256A1 (es) * 2017-10-02 2020-11-16 Merck Sharp & Dohme Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas
EP3676247B8 (en) * 2017-10-02 2023-04-12 Arixa Pharmaceuticals, Inc. Aztreonam derivatives and uses thereof
WO2019144969A1 (zh) 2018-01-29 2019-08-01 南京明德新药研发股份有限公司 用于治疗细菌感染的单环β-内酰胺化合物
CA3119394A1 (en) * 2018-11-13 2020-05-22 Nanjing Sanhome Pharmaceutical Co., Ltd. Monobactam compounds and use therefor
US12310948B2 (en) 2018-12-18 2025-05-27 Shenzhen Optimum Biological Technology Co., Ltd Application of monocyclic β-lactam compound in pharmacy
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
CN114828850B (zh) 2019-12-19 2024-08-13 深圳嘉科生物科技有限公司 化合物在制药中的应用
CN111253405B (zh) * 2020-03-20 2022-12-16 南京安伦化工科技有限公司 一种比阿培南中间体的制备方法
CN113754651B (zh) * 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
CN111592536B (zh) * 2020-06-04 2023-11-03 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺化合物及其制备方法和应用
CN115210231B (zh) * 2020-07-16 2024-10-08 宁夏农林科学院 单环内酰胺类化合物、其制备方法及其作为抗菌药的用途
EP4007759A4 (en) * 2020-08-06 2024-04-10 Ningxia Academy of Agriculture and Forestry Sciences BETA-LACTAM COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIAL AGENTS
CN112079791A (zh) * 2020-08-21 2020-12-15 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类抗生素侧链酸及其酯、其制备方法和应用
CN111909067B (zh) * 2020-08-28 2022-03-15 浙江凯普化工有限公司 一种d-青霉胺的有机全合成方法
AU2021473165B2 (en) * 2021-11-09 2025-05-22 Guangzhou HC New Drug Research Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING β-LACTAM COMPOUND AND USE THEREOF
JP7671398B2 (ja) * 2021-11-18 2025-05-01 メルク・シャープ・アンド・ドーム・エルエルシー クロマンアミジンモノバクタム抗生物質
US20250019376A1 (en) 2021-11-18 2025-01-16 Merck Sharp & Dohme Llc Chromane amidine monobactam antibiotics
CN118255695B (zh) * 2024-02-26 2025-03-14 广州艾奇西医药科技有限公司 一种β-内酰胺类化合物的中间体的纯化方法和制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794886A (fr) * 1972-02-22 1973-08-02 Pfizer Acides 6-(alpha-(omega-guanidinoalcanoylamino)acylamino)-penicillaniques
DE2458973A1 (de) * 1974-12-13 1976-06-16 Hoechst Ag Acylaminopenicillansaeuren und verfahren zu ihrer herstellung
DE2749265A1 (de) 1977-11-03 1979-05-10 Linde Ag Verfahren zur biologischen reinigung von abwasser
ZA806977B (en) * 1979-11-19 1981-10-28 Fujisawa Pharmaceutical Co 7-acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd 1−スルホ−2−オキソアゼチジン誘導体、その製造法および用途
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
NZ205642A (en) 1982-10-06 1986-08-08 Squibb & Sons Inc Beta-lactams and pharmaceutical compositions
US4638060A (en) 1985-04-29 1987-01-20 E. R. Squibb & Sons, Inc. O-sulfated spiro β-lactam hydroxamic acids
EP0336667A3 (en) 1988-04-04 1991-04-10 E.R. Squibb & Sons, Inc. [3S(Z)]-3-[[(2-amino-4-thiazolyl)[[2-(hydroxyamino)-2-oxoethoxy]imino]acetyl]-amino]-2,2-dimethyl-4-oxo-1-azetidinyl sulfate
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
CA2024282A1 (en) 1989-09-21 1991-03-22 Peter H. Ermann Heterocyclic hydrazide derivatives of monocyclic beta-lactam antibiotics
ZA918014B (en) 1990-11-05 1992-07-29 Squibb & Sons Inc Heteroaroyl derivatives of monocyclic beta-lactam antibiotics
US5250691A (en) 1991-09-09 1993-10-05 E. R. Squibb & Sons, Inc. Heteroaryl derivatives of monocyclic beta-lactam antibiotics
US5994340A (en) * 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
CA2422375C (en) 2000-09-14 2011-03-15 Pantherix Ltd. 3-(heteroaryl acetamido)-2-oxo-azetidine-1-sulfonic acids derivatives as antibacterial agents
CN1914151A (zh) 2004-01-27 2007-02-14 默克弗罗斯特公司 作为环氧合酶-2抑制剂的二芳基-2(5h)-呋喃酮类的释放一氧化氮的前药
ATE532514T1 (de) 2005-09-23 2011-11-15 Ms Science Corp Piperidin- und piperazinderivate
SI1965798T1 (sl) * 2005-12-07 2012-01-31 Basilea Pharmaceutica Ag Uporabni monobaktamski antibiotiki
JP5052495B2 (ja) 2006-02-14 2012-10-17 イハラケミカル工業株式会社 5−アルコキシ−4−ヒドロキシメチルピラゾール化合物の製造方法
JP2009530228A (ja) 2006-03-16 2009-08-27 アステラス製薬株式会社 セフェム化合物および抗菌薬としての利用
MX2009009918A (es) * 2007-03-23 2009-10-19 Basilea Pharmaceutica Ag Medicamentos combinados para el tratamiento de infecciones bacterianas.
WO2009049028A1 (en) 2007-10-09 2009-04-16 Targegen Inc. Pyrrolopyrimidine compounds and their use as janus kinase modulators
SG171781A1 (en) * 2008-12-19 2011-07-28 Pfizer Monocarbams

Also Published As

Publication number Publication date
US9556165B2 (en) 2017-01-31
ZA201405057B (en) 2017-09-27
PH12014501671A1 (en) 2014-11-10
MY173843A (en) 2020-02-24
MA35905B1 (fr) 2014-12-01
UA110880C2 (uk) 2016-02-25
WO2013110643A1 (en) 2013-08-01
IL233805A (en) 2016-06-30
MX346602B (es) 2017-03-24
EP2806873A1 (en) 2014-12-03
HK1203389A1 (zh) 2015-10-30
EA027126B1 (ru) 2017-06-30
HRP20161171T1 (hr) 2016-11-04
RS55210B1 (sr) 2017-01-31
UY34585A (es) 2013-09-02
PL2806873T3 (pl) 2016-12-30
CY1117955T1 (el) 2017-05-17
ME02532B (me) 2017-02-20
CU24273B1 (es) 2017-08-08
NZ626951A (en) 2016-03-31
ECSP14010249A (es) 2015-12-31
CL2014001956A1 (es) 2014-11-07
SMT201600354B (it) 2016-11-10
CA2862338A1 (en) 2013-08-01
LT2806873T (lt) 2016-10-10
KR102036393B1 (ko) 2019-10-24
PE20142345A1 (es) 2015-01-09
AU2013211575A1 (en) 2014-07-24
AU2013211575B2 (en) 2017-03-02
US9782390B2 (en) 2017-10-10
IL233805A0 (en) 2014-09-30
KR20140114390A (ko) 2014-09-26
US20150045340A1 (en) 2015-02-12
JP2015504907A (ja) 2015-02-16
EA201400838A1 (ru) 2014-12-30
BR112014017968A8 (pt) 2017-07-11
ES2592403T3 (es) 2016-11-30
SI2806873T1 (sl) 2016-10-28
TN2014000297A1 (en) 2015-12-21
MX2014008915A (es) 2014-08-26
SG11201403930XA (en) 2014-08-28
JP5869701B2 (ja) 2016-02-24
TW201343643A (zh) 2013-11-01
HUE030452T2 (en) 2017-05-29
CA2862338C (en) 2019-04-16
BR112014017968A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-06-20
CO7101240A2 (es) 2014-10-31
AP2014007880A0 (en) 2014-08-31
TWI659953B (zh) 2019-05-21
DK2806873T3 (en) 2016-08-29
CN104203237A (zh) 2014-12-10
PT2806873T (pt) 2016-09-23
EP2806873B1 (en) 2016-06-15
CU20140090A7 (es) 2014-12-26
PH12014501671B1 (en) 2020-02-28
AR089796A1 (es) 2014-09-17
US20170100379A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
IN2014MN01640A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JOP20180103A1 (ar) مركب صيدلاني
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
NZ743274A (en) Substituted tricyclic compounds as fgfr inhibitors
EA201270257A1 (ru) Производные n1-сульфонил-5-фторпиримидинона
IN2014DN09346A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
AU2014270524A8 (en) 2-phenylimidazo [1,2-a]pyrimidines as imaging agents
MX2012001618A (es) Derivados de 5-fluoropirimidinona.
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
IN2015DN00598A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU2012213775A8 (en) 7-azaindole derivatives
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
WO2012104823A3 (en) Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
IN2015DN00950A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN2015DN00085A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX374323B (es) Compuestos de heteroarilo y métodos de uso de los mismos.
WO2014172363A3 (en) Combretastatin analogs
AU2013347232A8 (en) 3-Aminocyclopentane carboxamide derivatives
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
IN2015DN02513A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN2012000381A1 (en) 2-aldoximino-5-fluoropyrimidine derivatives
UA106105C2 (uk) Застосування похідних 2-оксоіндолін-3-гліоксилової кислоти як засобів з антидепресивною дією